What do systematic reviews say?

Hepatitis B vaccination vs placebo

• Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Very low

Immunologic response to YF vaccine in HIV‐infected adults before HIV diagnosis, vs immunologic response to YF vaccine

Immunologic response to YF vaccine in HIV‐infected adults before HIV… may leads to lower immunogenicity: Adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (low certainty).

• Yellow fever vaccine for patients with HIV infection 2014 · Cochrane Headline outcomes only
  RR 0.91 [0.85, 0.98]
  1 study · 364 participants
  Low

Immunologic response to YF vaccine in HIV‐infected children vs immunologic response to YF vaccine

It is very uncertain whether immunologic response to YF vaccine in HIV‐infected children changes adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (very low certainty).

• Yellow fever vaccine for patients with HIV infection 2014 · Cochrane Headline outcomes only
  RR 0.23 [0.08, 0.64]
  1 study · 75 participants
  Very low

Immunologic response to YF vaccine in HIV‐infected adults vs immunologic response to YF vaccine

It is very uncertain whether immunologic response to YF vaccine in HIV‐infected adults changes immunogenicity: Adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (very low certainty).

• Yellow fever vaccine for patients with HIV infection 2014 · Cochrane Headline outcomes only
  RR 0.86 [0.77, 0.96]
  1 study · 144 participants
  Very low

Immunologic response to YF vaccine in HIV‐infected adults vs immunologic response to YF vaccine

It is very uncertain whether immunologic response to YF vaccine in HIV‐infected adults changes duration: Adequate antibody response (NT ≥1:10), compared with immunologic response to YF vaccine (very low certainty).

• Yellow fever vaccine for patients with HIV infection 2014 · Cochrane Headline outcomes only
  RR 0.88 [0.76, 1.02]
  1 study · 162 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 0.5 mg/kg compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 3 [0.11, 83.36]
  1 study · 19 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 40 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 2 mg/kg compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 27.44 [1.25, 601.57]
  1 study · 19 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 5 mg/kg compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 439.09 [25.73, 7493.14]
  2 studies · 40 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 10 mg/kg compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 145.67 [5.3, 4004.91]
  1 study · 21 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 162 mg weekly compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 24.82 [1.17, 527.12]
  1 study · 21 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 324 mg weekly compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 147 [5.35, 4037.48]
  1 study · 21 participants
  Very low

PRO 140 vs placebo

It is very uncertain whether PRO 140 changes antiviral response: 324 mg biweekly compared with placebo (very low certainty).

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  OR 57 [2.59, 1253.22]
  1 study · 22 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Very low

PRO 140 vs placebo

• Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Very low